Table 3.
Association of miR-106b-5p/FOG2 dysregulation with clinicopathological features of 130 hepatocellular carcinoma patients
| Clinicopathological Features | Case | miR-106b-5p-high/FOG2-low (n, %) | P |
|---|---|---|---|
| Age (years) | |||
| ≤50 | 72 | 26 (36.11) | NS |
| >50 | 58 | 14 (24.14) | |
| Gender | |||
| Male | 96 | 30 (31.25) | NS |
| Female | 34 | 10 (29.41) | |
| Serum AFP | |||
| Positive | 72 | 27 (37.50) | NS |
| Negative | 58 | 13 (22.41) | |
| Tumor stage | |||
| T1 | 23 | 1 (4.35) | <0.01 |
| T2 | 40 | 7 (23.33) | |
| T3 | 52 | 20 (38.46) | |
| T4 | 15 | 12 (80.00) | |
| Tumor grade | |||
| G1 | 31 | 4 (12.90) | <0.01 |
| G2 | 76 | 18 (23.68) | |
| G3 | 23 | 18 (78.26) | |
| Growth pattern | |||
| Trabecular | 101 | 32 (31.68) | NS |
| Nontrabecular | 29 | 8 (27.59) | |
| Cirrhosis | |||
| Yes | 86 | 28 (32.55) | NS |
| No | 44 | 12 (27.27) | |
Note: “NS” refers to the differences among groups have no statistical significance.